UP!
|
Type
|
Public |
|---|---|
| Traded as |
|
| Industry |
|
| Founded | 1976 |
| Founder | Dr. Roger C. Lucas |
| Headquarters | Minneapolis, Minnesota, United States |
|
Key people
|
Chuck Kummeth (President, CEO) |
| Products | 24,000 products, 14,000 of which are antibodies (2014) |
| Revenue |
|
|
Number of employees
|
>1,000 (2014) |
| Website | Bio-Techne |
| Footnotes / references |
|
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems (Research and Diagnostic Systems Inc.), Boston Biochem, Tocris Bioscience, BiosPacific and Bionostics. The company's products are used in both clinical and research contexts. The company was co-founded as a "hematology controls developer" by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.
Bio-Techne is listed on the NASDAQ under the ticker symbol TECH. Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...", a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch. Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."
Beginning in 2013, the company's chief executive officer was Chuck Kummeth, who had previously been employed by Thermo Fisher Scientific.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2023 | 2022-10-31 | Future report Set alerts | |
| Q4 2022 | 2022-08-04 | 2.05 | 2.05 |
| Q3 2022 | 2022-05-04 | 2.14 | 2.14 |
| Q2 2022 | 2022-02-01 | 1.88 | 1.88 |
| Q1 2022 | 2021-11-02 | 1.83 | 1.83 |
| Q4 2021 | 2021-08-05 | 0.00 | 0.00 |
| Q3 2021 | 2021-05-06 | 1.79 | 1.79 |
| Q2 2021 | 2021-02-02 | 1.62 | 1.62 |
| Q1 2021 | 2020-11-05 | 0.00 | 0.00 |
| Q4 2020 | 2020-08-04 | 1.00 | 1.48 |
| 2016-07-10 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-05 | Reiterated Rating | Leerink Swann | Hold | $105.00 |
| 2016-05-03 | Upgrade | Janney Montgomery Scott | Neutral to Buy | $100.00 to $118.00 |
| 2016-02-03 | Boost Price Target | Robert W. Baird | Outperform | $100.00 to $102.00 |
| 2015-11-02 | Lower Price Target | Craig Hallum | Buy | $125.00 to $110.00 |
| 2015-10-29 | Lower Price Target | Leerink Swann | $107.00 to $93.00 | |
| 2015-10-29 | Downgrade | Stephens | Overweight to Equal Weight | |
| 2015-10-28 | Downgrade | Janney Montgomery Scott | Buy to Neutral | |
| 2015-01-21 | Boost Price Target | Robert W. Baird | Outperform | $102.00 to $104.00 |
| 2014-12-10 | Upgrade | Janney Montgomery Scott | Neutral to Buy | |
| 2014-08-22 | Initiated Coverage | Stephens | Overweight | |
| 2014-08-12 | Reiterated Rating | Janney Montgomery Scott | Fair Value | $93.00 to $101.00 |
| 2014-04-29 | Boost Price Target | Leerink Swann | Market Perform | $86.00 to $93.00 |
| 2014-02-10 | Upgrade | William Blair | Market Perform to Outperform | |
| 2013-09-20 | Upgrade | Robert W. Baird | Neutral to Outperform | $76.00 to $90.00 |
| 2012-06-08 | Initiated | William Blair | Mkt Perform | |
| 2012-02-01 | Downgrade | Robert W. Baird | Outperform to Neutral | $81 to $71 |
| 2009-02-04 | Upgrade | Robert W. Baird | Neutral to Outperform | $76 to $69 |
| 2009-02-04 | Reiterated | Leerink Swann | Outperform | $73.50 to $59.50 |
| 2008-10-13 | Upgrade | Leerink Swann | Mkt Perform to Outperform | |
| 2008-04-18 | Downgrade | Robert W. Baird | Outperform to Neutral | $71 |
| 2007-09-07 | Downgrade | Leerink Swann | Outperform to Mkt Perform | |
| 2007-01-31 | Downgrade | First Analysis Sec | Overweight to Equal-Weight |
| 2016-07-10 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-05 | Reiterated Rating | Leerink Swann | Hold | $105.00 |
| 2016-05-03 | Upgrade | Janney Montgomery Scott | Neutral to Buy | $100.00 to $118.00 |
| 2016-02-03 | Boost Price Target | Robert W. Baird | Outperform | $100.00 to $102.00 |
| 2015-11-02 | Lower Price Target | Craig Hallum | Buy | $125.00 to $110.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TECH 370 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 4.49M |
| BlackRock Inc. | 4.33M |
| BlackRock Fund Advisors | 1.97M |
| STATE STREET CORP | 1.58M |
| Select Equity Group, L.P. | 1.48M |
| BAMCO INC /NY/ | 1.43M |
| BlackRock Institutional Trust Company, N.A. | 1.14M |
| Neuberger Berman Group LLC | 1.04M |
| JANUS CAPITAL MANAGEMENT LLC | 0.94M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.89M |
| WELLINGTON MANAGEMENT CO LLP | 0.85M |
| BROWN CAPITAL MANAGEMENT LLC | 0.82M |
| Winslow Capital Management, LLC | 0.69M |
| MAIRS & POWER INC | 0.67M |
| DF DENT & CO INC | 0.67M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| TECHNE CORP /MN/ | 16.85% (6235056) | TECH / |
| OLAND THOMAS E CEO, President | 3.18% (1177420) | TECH / |
| Kummeth Charles R. Chief Executive Officer | 0.23% (84472) | SPA / TECH / |
| OCONNELL HOWARD V | 0.19% (70000) | TECH / |
| VERONNEAU MARCEL VP Hematology Operations | 0.09% (34604) | TECH / |
| Dinarello Charles A | 0.02% (8212) | TECH / |
| BAUMGARTNER ROBERT V | 0.02% (7712) | TECH / |
| Nusse Roeland | 0.01% (4712) | TECH / |
| WIENS HAROLD J | 0.01% (4212) | TECH / |
| STEER RANDOLPH C | 0.01% (3712) | CAPS / TECH / VTL / |
| EANSOR N DAVID SVP - Novus Biologicals | 0.01% (3402) | TECH / |
| Hippel James Chief Financial Officer | 0.01% (3079) | TECH / |
| HIGGINS JOHN L | 0.01% (3012) | BCRX / LGND / TECH / |
| LUCAS ROGER C | 0.01% (1870) | CCXI / TECH / |
UM
$452M (2015)